The emergence of big data, as well as advancements in data science approaches and technology, is providing pharmaceutical companies with an opportunity to gain novel insights that can enhance and accelerate drug development.

It will increasingly help government health agencies, payers, and providers to make decisions about such issues as drug discovery, patient access, and marketing.

Source: hbr.org
Author: Ryan Copping and Michael Li